[HTML][HTML] Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Q Li, Y Tie, A Alu, X Ma, H Shi - Signal transduction and targeted …, 2023 - nature.com
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

[HTML][HTML] Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials

B Goel, AK Tiwari, RK Pandey, AP Singh, S Kumar… - Translational …, 2022 - Elsevier
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

[HTML][HTML] The renaissance of cyclin dependent kinase inhibitors

T Ettl, D Schulz, RJ Bauer - Cancers, 2022 - mdpi.com
Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …

[HTML][HTML] DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival

C Papalouka, M Adamaki, P Batsaki… - International Journal of …, 2023 - mdpi.com
Head and neck cancer (HNC) is a term collectively used to describe a heterogeneous group
of tumors that arise in the oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx …

[HTML][HTML] Combination therapy as a promising way to fight oral cancer

JPN Silva, B Pinto, L Monteiro, PMA Silva, H Bousbaa - Pharmaceutics, 2023 - mdpi.com
Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis
and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy …

[HTML][HTML] Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?

C Riess, N Irmscher, I Salewski, D Strüder… - Cancer and Metastasis …, 2021 - Springer
Cyclin-dependent kinases (CDK) control the cell cycle and play a crucial role in
oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical …

Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting

A Gupta, G Dagar, R Chauhan, HQ Sadida… - Advances in Protein …, 2023 - Elsevier
Regulated cell division is one of the fundamental phenomena which is the basis of all life on
earth. Even a single base pair mutation in DNA leads to the production of the dysregulated …

[HTML][HTML] An O-GlcNAcylomic Approach Reveals ACLY as a Potential Target in Sepsis in the Young Rat

M Denis, T Dupas, A Persello, J Dontaine… - International Journal of …, 2021 - mdpi.com
Sepsis in the young population, which is particularly at risk, is rarely studied. O-
GlcNAcylation is a post-translational modification involved in cell survival, stress response …

Protein O‐GlcNAcylation levels are regulated independently of dietary intake in a tissue and time‐specific manner during rat postnatal development

T Dupas, M Denis, J Dontaine, A Persello… - Acta …, 2021 - Wiley Online Library
Aim Metabolic sources switch from carbohydrates in utero, to fatty acids after birth and then a
mix once adults. O‐GlcNAcylation (O‐GlcNAc) is a post‐translational modification …

Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial

P Oppelt, JC Ley, F Worden, K Palka, R Maggiore, J Liu… - Oral Oncology, 2021 - Elsevier
Objectives We previously reported that palbociclib, a selective CDK4/6 inhibitor, given with
cetuximab, resulted in an objective response rate (ORR) of 19% in cetuximab-resistant …